Navigate Fool.com
Will SPPI beat
the market?
Community Rating: 3 Stars: Appealing

7.18 0.28 (4.06%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $7.25
Previous Close $6.90
Daily Range $6.95 - $7.56
52-Week Range $6.36 - $10.32
Market Cap $468.8M
P/E Ratio -6.76
Dividend (Yield) $0.00 (0.0%)
Volume 3,079,822
Average Daily Volume 975,391
Current FY EPS -$0.68

How do you think SPPI
will perform against the market?

Top SPPI Bull/Bear Pitches


mdriver78 (2.83)
Submitted February 16, 2011

Perhaps the FDA will approve Fusilev for mCRC on or before April 29, 2011. With FDA approval and full reimbursement, it is believed that many doctors will gravitate towards Fusilev. Here's why: Reli … More

3 Replies Reply Report this Post

zzlangerhans (< 20)
Submitted May 3, 2011

As expected, Spectrum's share price rose as much as 12% today on an expected FDA approval of Fusilev for colorectal cancer, which was already pretty much written into the share price. Spectrum at a 50 … More

11 Replies Reply Report this Post

News & Commentary

3 Under-the-Radar Biotech Stocks You Need to Watch in 2014

Nektar Therapeutics, Omeros, and Spectrum Pharmaceuticals all face off with regulators in key decision dates for their developmental drugs later this year

Is Spectrum Pharmaceuticals, Inc. Blazing the Comeback Trail?

Spectrum Pharmaceuticals has been one of the rare losers in the biopharma sector. That trend may be set to change, however, as the company has set itself up for long-term growth.

Why Thompson Creek Metals, Spectrum Pharmaceuticals, and FactSet Research Systems Tumbled Today

The stock markets moved modestly lower as investors wait for the Fed's decision Wednesday, but bad news sent Thompson Creek Metals down 10%, Spectrum Pharmaceuticals falling 9%, and FactSet Research Systems dropping 6%. What's behind the losses for these stocks? Find out here.

Mid-Afternoon Market Update: Markets Mixed as iRobot Surges

Mid-Day Market Update: U.S. Markets Extend Losses; Hewlett-Packard Shares Rise On Analyst Upgrade

Seattle Genetics Is Down but Not Out

Seattle Genetics share price has been trending lower lately due to adverse side effects experienced by some patients undergoing clinical trials with the company’s lead product Adcetris. Since long term prospects look bright forSeattle, this could be a nice chance for value investors to enter the stock.

Is Pessimism Warranted for These 3 Most Hated Biotech Stocks?

Short-sellers have dog-piled into these three biotech companies. Is their pessimism warranted or have emotions gotten the better of investors?

Could New Competition Create the Next Wave of Stock Losses for This Biotech?

Many think Amarin's initial struggles with Vascepa are normal, and that all bad news is priced into the stock. But with new competition rising, investors might want to buckle up for a Spectrum-like ride.

Here's What This Billion-Dollar Market Wizard Has Been Buying

It can pay off to keep an eye on big investors.

Spectrum Pharmaceuticals to Present Corporate Update at the Morgan Stanley Global Healthcare Confere

See More SPPI News...





Spectrum Pharmaceuticals, Inc. (SPPI) Description

A biopharmaceutical company that acquires and advances a diversified portfolio of drug candidates, with a focus on oncology, urology and other critical health challenges for which there are few other treatment options. Website: http://www.sppirx.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks